AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 OCT 7 - (NewsRx.com & NewsRx.net) -- Researchers with the U.S. National Cancer Institute recently provided an overview on the development of therapeutic nucleic acids to target cervical cancer.
"Cervical cancer is the second most common neoplastic disease affecting women worldwide. Basic, clinical, and epidemiological analyses indicate that expression of high-risk human papillomaviruses (HPVs) E6/E7 genes is the primary cause of cervical cancer and represent ideal targets for the application of therapeutic nucleic acids (TNAs)," wrote J.A. DiPaolo and colleagues.
According to the researchers, "Antisense oligodeoxyribonucleotides (AS-ODNs) and ribozymes (RZs) are the most effective TNAs able to inhibit in vivo tumor growth by eliminating HPV-16 and HPV-18 E6/E7 transcripts. Expression of multiple RZs directed against alternative target sites by triplex expression systems may result in the abrogation of highly variable HPVs.
"More recently," they continued, "RNA interference (RNAi) gene knockdown phenomenon, induced by small interfering RNA (siRNA), has demonstrated its potential value as an effective TNA for cervical cancer.
"siRNA and ...
Source: HighBeam Research, Development of therapeutic nucleic acids is ongoing.